8 / 16
†
Access to OPDIVO monotherapy is available now
from BMS in line with the Product Information and
program eligibility criteria.
1
For further information
and enquiries regarding access to OPDIVO,
please contact your local BMS representative.
PBS Information: This product is not listed on the PBS
WARNING: IMMUNE-RELATED ADVERSE REACTIONS WITH OPDIVO AND YERVOY (IPILIMUMAB) COMBINATION THERAPY.
Physicians should consult the YERVOY product information prior to initiation of OPDIVO in combination with YERVOY. It is recommended that the combination of OPDIVO
and YERVOY should be administered and monitored under the supervision of physicians experienced with the use of immunotherapy in the treatment of unresectable or
metastatic melanoma. More frequent, and more serious, immune-related adverse reactions are seen with OPDIVO and YERVOY combination therapy than with the use of
single agent nivolumab or ipilimumab. OPDIVO and YERVOY combination therapy can cause a wide range of potentially life-threatening immune-related adverse reactions
including pneumonitis, hepatitis, diarrhoea/colitis, rash, hypophysitis and thyroid dysfunction, as well as immune-related adverse reactions in other organ systems. Early
diagnosis and appropriate management are essential to minimise life-threatening complications (see PRECAUTIONS, ADVERSE EFFECTS and DOSAGE & ADMINISTRATION).
Please refer to the Approved Product Information before prescribing. The Product Information is available upon request from
BMS Medical Information Department: 1800 067 567 or can be accessed at
http://www.medicines.org.au/files/bqpopdiv.pdfALK = Anaplastic lymphoma receptor tyrosine kinase; EGFR = Epidermal growth factor receptor; NSCLC = Non-small cell lung cancer.
Reference: 1.
OPDIVO (nivolumab) Approved Product Information, February 2016.
© 2016 Bristol-Myers Squibb. OPDIVO
®
is a registered trademark of Bristol-Myers Squibb Company.
BMS Medical Information:
1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, 4 Nexus Court,
Mulgrave, VIC 3170. NIV/0111/02-16. Date of preparation: February 2016. BMSA0070.
Start OPDIVO now
†